
FTC hails ‘win for consumers’ after planned $320M hospital deal is dropped
The Federal Trade Commission made its first comments after Novant Health dropped plans to buy two hospitals from Community Health Systems. Regulators have spurred several hospitals to abandon planned mergers.
Federal regulators have succeeded in deterring a number of planned hospital deals over the last few years, and they are touting another victory.
The Federal Trade Commission has offered its first comments after
Federal regulators said that the Novant purchase would lead to higher prices and the potential for reduced services due to less competition in the market. Henry Liu, the FTC’s bureau of competition director, pointed to similar themes in a statement Monday.
“Hospital consolidation diminishes quality of care and increases costs for critical services,” Liu said in the statement. “Novant’s deal with Community Health Systems would have followed this same trend to the detriment of North Carolinians.”
“The FTC’s opposition to the transaction has been vindicated by the injunction pending appeal, granted by the Fourth Circuit Court of Appeals,” he added. “In ruling on the injunction, the Fourth Circuit examined the FTC’s likelihood of success on appeal, among other factors. Novant’s and CHS’s decision to abandon their anticompetitive transaction after this ruling is a win for consumers.”
Steep opposition
Novant had planned to buy Lake Norman Regional Medical Center and Davis Regional Medical Center from Community Health Systems.
Regulators said the deal would give Novant nearly 65% of the market for inpatient acute care in North Carolina’s Eastern Lake Norman area. The FTC argued that the Novant-CHS deal would result in less competition, and thus less incentive to maintain services and keep prices affordable.
“With this deal off the table, Novant and Community Health Systems will continue to compete against one another, delivering better outcomes for patients in both quality of care and price,” Liu said in the statement.
Novant pledged to make substantial investments in the facilities. When Novant announced it would no longer pursue the deal last month, the system also delivered sharp criticism of the FTC.
“Despite our vision to restore services the area has lost and deliver high quality, remarkable care, we have been met with opposition from the Federal Trade Commission at every step,” Novant said in a statement. “We are steadfast in our belief that these facilities and their patients would have greatly benefited from joining Novant Health, but with the FTC’s continued roadblocks we do not see a way to finalize this transaction.”
The appeals court delivered a 2-1 ruling that
In his dissenting opinion, Judge J. Harvie Wilkinson III wrote that he agreed with a federal district judge’s argument that the deal would benefit the public. Wilkinson cited concerns that if the deal doesn’t go through, that Davis Regional Medical Center could possibly close. CHS closed the hospital in 2022 for financial reasons and converted it into a behavioral health facility.
Wilkinson also chastised federal regulators in his dissent, writing, “The FTC is acting too aggressively in this case, forgetting there is such a thing as a vibrant private sector.”
In his ruling in June in favor of Novant’s plans, U.S. District Judge Kenneth Bell wrote that there would be sufficient competition in the region. Bell noted that Atrium Health, part of
The FTC secured the injunction just two weeks after Novant secured what appeared to be a key
Novant, which operates 19 medical centers and more than 850 healthcare sites, fared more successfully with another recent deal. In February,
Other stalled deals
As the planned Novant-CHS deal shows, the FTC is willing to move aggressively to block deals if the commission finds there will be reduced competition, particularly for deals involving systems in the same region.
Kevin Holloran, senior director for
“We're still living in an environment right now, at a federal and even a state level … that is kind of anti-merger, if you will,” Holloran said. “And I'm not saying it's good or bad, just that it is what we're operating under.”
In addition,
Two Rhode Island hospital systems, Lifespan and Care New England, had planned a merger, but
Moody’s Investors Services also pointed to regulators’ skepticism of some hospital mergers in
There were
So plenty of deals are happening, but hospitals and health systems are seeing that a planned merger or acquisitions may not be an easy sell to regulators.








































